Literature DB >> 29421273

Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.

Malte Lenders1, Boris Schmitz2, Stefan-Martin Brand2, Dirk Foell3, Eva Brand4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29421273     DOI： 10.1016/j.jaci.2017.12.1001

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  11 in total

Review 1.  Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

Authors:  Malte Lenders; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2018-08-09       Impact factor: 10.121

2.  Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond.

Authors:  Michał Nowicki; Stanisława Bazan-Socha; Mariusz Kłopotowski; Beata Błażejewska-Hyżorek; Mariusz Kusztal; Krzysztof Pawlaczyk; Jarosław Sławek; Andrzej Oko; Zofia Oko-Sarnowska
Journal:  Int J Environ Res Public Health       Date:  2021-08-04       Impact factor: 3.390

3.  Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.

Authors:  Malte Lenders; Leon Paul Neußer; Michael Rudnicki; Peter Nordbeck; Sima Canaan-Kühl; Albina Nowak; Markus Cybulla; Boris Schmitz; Jan Lukas; Christoph Wanner; Stefan-Martin Brand; Eva Brand
Journal:  J Am Soc Nephrol       Date:  2018-11-01       Impact factor: 10.121

Review 4.  Fabry Disease: The Current Treatment Landscape.

Authors:  Malte Lenders; Eva Brand
Journal:  Drugs       Date:  2021-03-15       Impact factor: 9.546

5.  Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?

Authors:  Malte Lenders; Boris Schmitz; Stefan-Martin Brand; Eva Brand
Journal:  Orphanet J Rare Dis       Date:  2018-09-29       Impact factor: 4.123

6.  Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.

Authors:  Wladimir Mauhin; Olivier Lidove; Damien Amelin; Foudil Lamari; Catherine Caillaud; Federico Mingozzi; Gaëlle Dzangué-Tchoupou; Louiza Arouche-Delaperche; Claire Douillard; Bertrand Dussol; Vanessa Leguy-Seguin; Pauline D'Halluin; Esther Noel; Thierry Zenone; Marie Matignon; François Maillot; Kim-Heang Ly; Gérard Besson; Marjolaine Willems; Fabien Labombarda; Agathe Masseau; Christian Lavigne; Roseline Froissart; Didier Lacombe; Jean Marc Ziza; Eric Hachulla; Olivier Benveniste
Journal:  Orphanet J Rare Dis       Date:  2018-07-31       Impact factor: 4.123

7.  Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease.

Authors:  Wladimir Mauhin; Olivier Lidove; Olivier Benveniste
Journal:  Orphanet J Rare Dis       Date:  2019-01-07       Impact factor: 4.123

Review 8.  Immunogenicity of Protein Therapeutics: A Lymph Node Perspective.

Authors:  Kristy Fu; Kylie March; Aikaterini Alexaki; Giulia Fabozzi; Eirini Moysi; Constantinos Petrovas
Journal:  Front Immunol       Date:  2020-05-14       Impact factor: 7.561

9.  Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.

Authors:  Malte Lenders; Eva Brand
Journal:  Drugs       Date:  2021-11-08       Impact factor: 9.546

10.  Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.

Authors:  Malte Lenders; David Scharnetzki; Ali Heidari; Daniele Di Iorio; Seraphine Valeska Wegner; Eva Brand
Journal:  Int J Mol Sci       Date:  2021-03-06       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.